At the 5th International Symposium on Frontiers in Molecular Science (Kyoto, 26–29 August 2025), Dr. Florian Kongoli, President of FLOGEN Technologies, delivered a keynote on integrating sustainability into molecular science and drug development.
He presented the FLOGEN Sustainability Framework, which ensures that every innovation meets three essential pillars:
Environmental Protection
Economic Development
Social Development
Dr. Kongoli emphasized how AI and accelerated research make drug development faster, more sustainable, and more affordable, particularly for diseases such as Alzheimer’s and Parkinson’s.
He also addressed a pressing healthcare issue: medical errors and malpractice. In high-income countries, 1 in 10 patients is harmed during hospital care, and nearly 30% of these cases result in death, while only a fraction of victims ever receive justice. Dr. Kongoli argued that data science, technology, and structured sustainability frameworks are crucial to reducing harm and achieving true progress in healthcare.
Dr. Florian Kongoli: Lecture at 5th International Symposium on Frontiers in Molecular Science
August 2025 Events
DAVIS JOSEPH UNVEILS UNIFIED THEORY OF NEURODEGENERATION IN KYOTO447
Davis Joseph, Director of Biochemistry at FLOGEN Technologies Inc. (Canada), presented a historic breakthrough at the 5th International Symposium on Frontiers in Molecular Science.
At just 23, Joseph discovered that axon-based deamidation of the 4E-BP2 protein is the key driver of neurodegeneration. This finding, known as Davis Joseph’s Principle, redefines how the brain regulates protein synthesis and unites the causes of Alzheimer’s, Parkinson’s, and related diseases under a single mechanism.
His Unified Theory of Neurodegeneration shows that by restoring deamidation to normal values, multiple diseases long studied as separate can be cured with one approach.
Joseph’s two landmark publications in the International Journal of Molecular Sciences have set world records in readership and been covered by over 1,100 media outlets worldwide. Nobel Laureates have described his work as "Nobel Prize worthy."
Pharmaceutical applications targeting axon-specific deamidation are already underway, with potential to revolutionize medicine and create an industry valued at nearly $1 trillion.
Davis Joseph: Lecture at 5th International Symposium on Frontiers in Molecular Science
Davis Joseph’s second single-author article, The Unified Theory of Neurodegeneration Pathogenesis Based on Axon Deamidation, reached 6,000 downloads in just 4 months https://lnkd.in/d9a8VgEy
The paper reveals a common “master switch” for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. His first article already broke records with 11,000 accesses in 9.5 months, https://lnkd.in/dJ9SHV_p earning him the Semenza International Award, presented by Nobel Laureate Gregg Semenza.
Now invited for a plenary lecture at SIPS 2026 (Cebu, Philippines), Joseph’s achievement stands out as a rare single-author breakthrough in an era dominated by multi-author research.
August 2025 Events
GRATEFUL TO OUR PLATINUM SPONSOR: FLOGEN TECHNOLOGIES INC.450
Sciforum extends its appreciation to the event’s Platinum Sponsor, FLOGEN Technologies Inc., for providing outstanding support at The 5th International Symposium on Frontiers in Molecular Science (ISFMS 2025).
The generous support and contributions of FLOGEN Technologies Inc. were a key factor in the success of the event.
Special thanks from Sciforum to Dr. Florian Kongoli(CEO), Biochemistry Director Davis Joseph, and the FLOGEN Technologies Inc. team for their dedication and commitment.
